Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
2015 · Blood · 692 citations
https://doi.org/10.1182/blood-2015-06-651125
P
Petra Langerbeins
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
108
Papers
2.4K
Citations
23
h-index
33
i10-index
Petra Langerbeins is an academic researcher from Düsseldorf University Hospital. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 23, co-authored 92 publications.
ORCID: 0000-0002-6654-0304Papers by this author
worksMRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
2025 · Blood · 7 citations
https://doi.org/10.1182/blood.2024026685
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
2019 · American Journal of Hematology · 6 citations
https://doi.org/10.1002/ajh.25561
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
2024 · Journal of Clinical Oncology · 6 citations
https://doi.org/10.1200/jco.24.00975
Hybrid immunity to <scp>SARS‐CoV</scp> ‐2 in patients with chronic lymphocytic leukemia
2024 · European Journal Of Haematology · 2 citations
https://doi.org/10.1111/ejh.14170
CLL-984: CLL18/MOIRAI International Phase 3 Trial: Aiming to Establish Measurement of Individual Residual Disease for Adjustment of Treatment Duration to Improve Outcomes in First-Line Treatment of CLL/SLL
2025 · Clinical Lymphoma Myeloma & Leukemia · 2 citations
https://doi.org/10.1016/s2152-2650(25)01874-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat